Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Persistent microbiome dysbiosis following hematopoietic cell transplantation: Gut GvHD as the most severe manifestation of microbial disruption

Hasan Hashem, Muna Al Zughbieh, Rawad Rihani et al. Nov 03, 2025 pp. 2465-2465 10.1182/blood-2025-2465

Abstract Background Hematopoietic cell transplantation conditioning regimens severely disrupt the gut microbiome, potent...

Daratumumab with dose-adjusted EPOCH feasibility and early efficacy in newly diagnosed plasmablastic lymphoma: AIDS malignancy consortium 105

Ariela Noy, Stefan Barta, Grace Van Hyfte et al. Nov 03, 2025 pp. 1970-1970 10.1182/blood-2025-1970

Abstract Background: Plasmablastic lymphoma (PBL) is commonly associated with HIV, immunosuppression, old age, and autoimmune disorders, but...

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

Marie Scully, Paul Coppo, Masanori Matsumoto et al. Nov 03, 2025 pp. 848-848 10.1182/blood-2025-848

Abstract Introduction Data from the final analysis of a phase 3 study (NCT03393975) that investigated the efficacy and s...

Pregnancy related complications and placenta pathology in pregnant women with sickle cell disease

Nneka Nwachukwu, Abraham Attah, Mohamad Ali Tfaily et al. Nov 03, 2025 pp. 4744-4744 10.1182/blood-2025-4744

Abstract Background: Among pregnant women with sickle cell disease (SCD), studies have shown an increased risk of complications such as mate...

Spatial communication modules identify prognostic cell-cell signaling hubs in chronic graft-versus-host disease

Bruno Fernandes Matuck, Khoa Huynh, Deiziane de Souza et al. Nov 03, 2025 pp. 5864-5864 10.1182/blood-2025-5864

Abstract Introduction : Chronic graft-versus-host disease (GVHD) is a leading cause of late non-relapse mortality following allogeneic hemat...

Phenotype–Genotype characterization of inherited Protein C deficiency in a qatari family

Sara Jemmieh, Reem AL Sulaiman, Aliaa Amer et al. Nov 03, 2025 pp. 6668-6668 10.1182/blood-2025-6668

Abstract Background Protein C deficiency is an autosomal dominant thrombophilia caused by pathogenic variants in the PROC gene. Heterozygous...

Allogeneic hematopoietic cell transplantation in TP53-mutated Acute Myeloid Leukemia patients with active disease: A study from the global committee and the acute leukemia working party of the EBMT

Lin Li, Yishan Ye, Allain Thibeault Ferhat et al. Nov 03, 2025 pp. 2523-2523 10.1182/blood-2025-2523

Abstract Background Acute myeloid leukemia (AML) harboring TP53 mutations is notoriously challenging to manage, frequently showing resistanc...

Expansion of human hematopoietic stem cells by inhibiting translation

Chenchen Li, Hanna Shin, Dheeraj Bhavanasi et al. Nov 03, 2025 pp. 1379-1379 10.1182/blood-2025-1379

Abstract Hematopoietic stem cell (HSC) transplantation using umbilical cord blood (UCB) is a potentially life-saving treatment for leukemia...

Dynamic crosstalk between CLL cells and lymph node fibroblasts promotes a pro-tumor microenvironment

Yu-Ju Chen, António Ferreira, Kelly Wong et al. Nov 03, 2025 pp. 241-241 10.1182/blood-2025-241

Abstract Chronic lymphocytic leukemia (CLL) relies heavily on microenvironmental support within secondary lymphoid organs, especially lymph...

Polatuzumab-vedotin in large diffuse B-cell lymphoma: A multicenter observational study from Latin America (2020–2024)

Diana Sotelo, Manuela Estrada, Nicolas Duque et al. Nov 03, 2025 pp. 7200-7200 10.1182/blood-2025-7200

Abstract Introduction: Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug conjugate linked to monomethyl auristatin...

The fertility outcome in a cohort of SCD patients undergoing haploidentical allogeneic stem cell transplant using NMA regimen.

Mazin Mohamed Abdulsalam, Mohsen Alzahrani, Ahmed Alaskar et al. Nov 03, 2025 pp. 2485-2485 10.1182/blood-2025-2485

Abstract Abstract title: The fertility outcome in a cohort of SCD patients undergoing haploidentical allogeneic stem cell transplant using N...

Peripheral cytopenias and bone marrow findings in patients with liver failure: A ten-year retrospective analysis at a high-volume transplant center

Ricardo Vallejo Calzada, James Gore, Paul Thevenot et al. Nov 03, 2025 pp. 4389-4389 10.1182/blood-2025-4389

Abstract Introduction: Peripheral blood abnormalities are a common occurrence in patients with chronic liver disease. Thrombocytopenia is of...

Novel criteria for evaluating early treatment response with whole body magnetic resonance imaging and prognostic implications in patients with newly diagnosed multiple myeloma

Ioannis Ntanasis-Stathopoulos, Vassilis Koutoulidis, Maria Gavriatopoulou et al. Nov 03, 2025 pp. 5765-5765 10.1182/blood-2025-5765

Abstract Introduction: Whole-body magnetic resonance imaging (WBMRI) is a highly sensitive technique to detect focal lesions in patients (pt...

Molecular and functional determinants of response to venetoclax and inotuzumab ozogamicin in CD22-positive ALL

Stella Jaeckle, Emma Smith, Jeremy Ryan et al. Nov 03, 2025 pp. 329-329 10.1182/blood-2025-329

Abstract Introduction: Venetoclax (VEN) is a selective BCL-2 inhibitor with clinical activity in subsets of patients with ALL (Del Gaizo Blo...

Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO)

Raúl Córdoba, Maria Carmen Martinez Munoz, Rosa Maria Rodriguez Nunez et al. Nov 03, 2025 pp. 6264-6264 10.1182/blood-2025-6264

Abstract Introduction. The outcomes of older adults with classical Hodgkin Lymphoma (cHL) have improved in recent decades. However, despite...

Whole genome sequencing reveals that the Philadelphia chromosome (Ph) can evolve and gain complex chromoplectic sequence rearrangements associated with tyrosine kinase inhibitor (TKI) resistance

Susan Branford, Carol Wadham, Nur Hezrin Shahrin et al. Nov 03, 2025 pp. 3770-3770 10.1182/blood-2025-3770

Abstract Background Understanding of the heterogeneity in the formation of the Ph has evolved as technology has advanced. In the pre-TKI era,...

RBC cultured from immortalized erythroblasts that express ectopic antigens induce antigen specific immune responses

Youmna Al Halabi, Eelke Brandsma, Nurcan Yagci et al. Nov 03, 2025 pp. 543-543 10.1182/blood-2025-543

Abstract Introduction: The exposure to foreign alloantigens upon pregnancy or after receiving red blood cell (RBC) trans...

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Salomon Manier, Jérôme Lambert, Magaret Macro et al. Nov 03, 2025 pp. 367-367 10.1182/blood-2025-367

Abstract Background. Teclistamab is a subcutaneous bispecific IgG4 antibody targeting BCMA on myeloma cells and CD3 on T cells, enabling T-c...

Developing epigenetic synergistic drug combinations with albendazole in paediatric acute myeloid leukaemia

Sophie Carlin, Seodhna Lynch, Declan McKenna et al. Nov 03, 2025 pp. 6788-6788 10.1182/blood-2025-6788

Abstract Acute myeloid leukaemia (AML) is an aggressive malignancy that account for ~25% of all paediatric cancers (Tebbi 2021). Over the la...

Efficacy and safety of bridging versus non-bridging chimeric antigen receptor t-cell therapy in relapsed/refractory diffuse large b-cell lymphoma : A systematic review and meta-analysis

Sharvani Alajpur, Karna Desai, Greeshma Gaddipati et al. Nov 03, 2025 pp. 7242-7242 10.1182/blood-2025-7242

Abstract Introduction:Chimeric antigen receptor T-cell (CART) therapy has become the standard of care for patients with relapsed/refractory...

Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study

Yasuyuki Arai, Marie Ohbiki, Mio Kurata et al. Nov 03, 2025 pp. 4289-4289 10.1182/blood-2025-4289

Abstract Background: Gilteritinib, a FLT3 inhibitor, is widely used for relapse or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML...

Efficacy and safety of tranexamic acid in non-haemophilia bleeding disorders: A systematic review of randomized controlled trials

Manpal Sandhu, Puneet Kaur, Cheryl Singla et al. Nov 03, 2025 pp. 3082-3082 10.1182/blood-2025-3082

Abstract BACKGROUND Tranexamic acid (TXA) is a synthetic antifibrinolytic agent widely used to reduce bleeding in surgical procedures, trauma...

In vitro microfluidics model revealed red blood cell derived extracellular vesicles cause second hit to heme-primed endothelial cells

Qingrong He, Chang Liu, Tripti Halder et al. Nov 03, 2025 pp. 4711-4711 10.1182/blood-2025-4711

Abstract Introduction: Sickle cell disease (SCD) is a genetic hemoglobinopathy associated with increased red blood cell (RBC) rigidity and s...

The role of xdh and hprt1 on purine metabolism in hematopoiesis and leukemia

Zhu Qianzhe, Jiaming Guo, Bo Shen Nov 03, 2025 pp. 1375-1375 10.1182/blood-2025-1375

Abstract In mammalian cells, purine metabolism is essential for nucleic acid synthesis, redox balance, and energy homeostasis, involving den...

Timing of tyrosine kinase inhibitor switching and long-term outcomes in chronic myeloid leukemia: A real-world comparative study

Chidiebube Ugwu, Muluken Megiso, Elvis Obomanu et al. Nov 03, 2025 pp. 7945-7945 10.1182/blood-2025-7945

Abstract Background: In chronic myeloid leukemia (CML), switching tyrosine kinase inhibitors (TKIs) is often necessary due to intolerance, i...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page